Professor Steven Nissen, Cleveland Clinic, Ohio, USA, discusses Phase 2 data of the Lp(a) lowering effects of pelacarsen in patients with cardiovascular disease and elevated Lp(a), and looks at the fully enrolled Phase 3 Lp(a) Horizon trial which is investigating the effects of pelacarsen on MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or urgent coronary revascularisation).
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)